i-standard multi-drug regime which aims at reversing transcription by either preventing further viral DNA elongation, inhibiting protease, binding the viral DNA enzyme, using brad spectrum inhibitors all in attempt to keep the HIV virus from multiplying (UCSF, 2010).
Primarily, low t-cell count is the sole determinant of the progression and infection rate of the HIV and AIDS patients, and the only option the patients have is taking the standard-multi drug regime which have adverse side effects. However, the new developed powerful drug will helps raise t-cell counts in AIDS patients and retard disease progression for those who have been in decline for years or months therefore offering the same level of efficiency derived by taking “cocktail” of powerful medications. The new drug is believed to be as efficient as the standard multi-drug regimen. With the average efficiency of the new drug µ1 and µ2 being the average efficiency of the latter, the hypothesis will be represented as follows:
Considering that the new drug’s efficiency will be compared to the multi-drug regimen, an applicable definition of efficiency will be considered. In this respect, efficiency will be defined as the drug’s ability to produce certain effects on the patient without respect to the quantity administered (Pokrovskii & Kompaniets, 2008).
The 60 AIDS infected persons will be selected through random assignment which will be targeted from the Annual AIDS campaign day where all countrywide affected and infected persons gather. At the campaign, the new drug benefits and possible side effects will be clearly elaborated and patients interested in both control and experimental group asked to volunteer. A group of 100 patients have to be tested for their t-cells blood counts. Among them, 20 of them must have been in decline for months or years. From the names, 30 patients will randomly be picked as the Control Group including 10 patients among the tested 20 who have been in decline for